CDK4/6 Inhibition Triggers ICAM1-Driven Immune Response and Sensitizes LKB1-Mutant Lung Cancer to Immunotherapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Nature Communications
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
CDK4/6 inhibition triggers ICAM1-driven immune response and sensitizes LKB1 mutant lung cancer to immunotherapy
Nat Commun 2023 Mar 04;14(1)1247, X Bai, ZQ Guo, YP Zhang, ZZ Fan, LJ Liu, L Liu, LL Long, SC Ma, J Wang, Y Fang, XR Tang, YJ Zeng, X Pan, DH Wu, ZY DongFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.